TrialLeukemia research2017

Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia.

Jonathan A Webster et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.